{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T23:54:28Z","timestamp":1784159668902,"version":"3.55.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Scleroderma & Raynaud\u2019s United Kingdom"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The aim of this study was to validate the Patient self-Assessment of Skin Thickness in Upper Limb (PASTUL) questionnaire in SSc and assess impact of skin involvement on health-related quality of life (HRQoL).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Participants were included in four UK centres. PASTUL specifies a grading of skin at eight sites corresponding to the modified Rodnan Skin Score (mRSS). Construct validity was assessed by comparing PASTUL scores with mRSS. HRQoL was evaluated with EuroQoL 5 dimension 5 levels (EQ5D5L) and Leeds SSc QoL questionnaires. Additionally, correlation between PASTUL and Scleroderma Skin Patient-Reported Outcome (SSPRO) was explored. Follow-up was 12\u2009months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 196 participants were included, mean age was 56.4\u2009years (s.d. 13.9), 80.6% female (n\u2009=\u2009158), mean disease duration 11.9\u2009years (s.d. 9.9), 110 (56.1%) had lcSSc and 81 (41.3%) dcSSc. PASTUL and upper limb mRSS were well correlated at baseline, 6 and 12\u2009months [intraclass correlation coefficients (ICC)\u2009=\u20090.67, 0.78 and 0.62, P\u2009&amp;lt;\u20090.001]. Test\u2013retest reliability was good (ICC\u2009=\u20090.83, P\u2009&amp;lt;\u20090.001). There was a stronger correlation between PASTUL and upper limb mRSS in dcSSc compared with lcSSc (0.69 vs 0.51, P\u2009&amp;lt;\u20090.001). In participants with early disease (&amp;lt;4\u2009years) PASTUL was moderately correlated with HRQoL (r\u2009=\u20090.53, P\u2009&amp;lt;\u20090.001); correlations were weaker in the whole group. Mean time to do the PASTUL self-assessment was 5.0\u2009min (s.d. 3.7).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>PASTUL is a feasible outcome tool that adds to assessments such as SSPRO. Skin thickening is correlated with HRQoL, particularly in early disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae561","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T15:03:07Z","timestamp":1728918187000},"page":"2802-2809","source":"Crossref","is-referenced-by-count":4,"title":["Self-reported skin severity and quality of life in systemic sclerosis: multicentre validation of PASTUL"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2546-312X","authenticated-orcid":false,"given":"Julia","family":"Spierings","sequence":"first","affiliation":[{"name":"Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School Royal Free Campus , London,","place":["UK"]},{"name":"Department of Rheumatology & Clinical Immunology, University Medical Centre Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paco M J","family":"Welsing","sequence":"additional","affiliation":[{"name":"Department of Rheumatology & Clinical Immunology, University Medical Centre Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5703-6739","authenticated-orcid":false,"given":"Seda","family":"Colak","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds , Leeds,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Quah","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School Royal Free Campus , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8528-2283","authenticated-orcid":false,"given":"Francesco","family":"Del Galdo","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds , Leeds,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4941-7926","authenticated-orcid":false,"given":"Ariane L","family":"Herrick","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal & Dermatological Sciences, The University of Manchester & Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester,","place":["UK"]},{"name":"NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3361-4909","authenticated-orcid":false,"given":"Michael","family":"Hughes","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal & Dermatological Sciences, The University of Manchester & Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2793-2364","authenticated-orcid":false,"given":"John D","family":"Pauling","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, North Bristol NHS Trust , Bristol,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5474-0053","authenticated-orcid":false,"given":"Voon H","family":"Ong","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School Royal Free Campus , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3975-8938","authenticated-orcid":false,"given":"Christopher P","family":"Denton","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School Royal Free Campus , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"key":"2025050316133226600_keae561-B1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"2025050316133226600_keae561-B2","first-page":"84","article-title":"The modified rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis","volume":"25","author":"Furst","year":"1998","journal-title":"J Rheumatol"},{"issue":"Suppl 5","key":"2025050316133226600_keae561-B3","doi-asserted-by":"crossref","first-page":"v44","DOI":"10.1093\/rheumatology\/ken309","article-title":"Skin involvement in systemic sclerosis","volume":"47","author":"Czirj\u00e1k","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"2025050316133226600_keae561-B4","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1002\/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q","article-title":"Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial","volume":"43","author":"Clements","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2025050316133226600_keae561-B5","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/annrheumdis-2016-210503","article-title":"Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)","volume":"76","author":"Herrick","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025050316133226600_keae561-B6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/1756-185X.13035","article-title":"Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease","volume":"20","author":"Boulos","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"2025050316133226600_keae561-B7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/acr.23282","article-title":"Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo-controlled trials","volume":"70","author":"Namas","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2025050316133226600_keae561-B8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/2397198321999927","article-title":"Impact of Covid-19 on clinical care and lived experience of systemic sclerosis: an international survey from EURORDIS-Rare Diseases Europe","volume":"6","author":"Hughes","year":"2021","journal-title":"J Scleroderma Relat Disord"},{"key":"2025050316133226600_keae561-B9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41584-020-00527-5","article-title":"How COVID-19 is changing rheumatology clinical practice","volume":"17","author":"Bonf\u00e1","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"2025050316133226600_keae561-B10","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/annrheumdis-2020-219775","article-title":"PASTUL questionnaire: a tool for self-assessment of scleroderma skin during the COVID-19 pandemic","volume":"80","author":"Spierings","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025050316133226600_keae561-B11","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2025050316133226600_keae561-B12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5301\/jsrd.5000231","article-title":"Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis","volume":"2","author":"Khanna","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"2025050316133226600_keae561-B13","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/art.1780401110","article-title":"The value of the Health Assessment Questionnaire and special patient- generated scales to demonstrate change in systemic sclerosis patients over time","volume":"40","author":"Steen","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2025050316133226600_keae561-B14","author":"Reay","year":"2008"},{"key":"2025050316133226600_keae561-B15","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1136\/annrheumdis-2017-212412","article-title":"Common measure of quality of life for people with systemic sclerosis across seven European countries: a cross-sectional study","volume":"77","author":"Ndosi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025050316133226600_keae561-B16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12955-015-0356-8","article-title":"Assessing the health of the general population in England: how do the three- and five-level versions of EQ-5D compare? Health Qual","volume":"13","author":"Feng","year":"2015","journal-title":"Life Outcomes"},{"key":"2025050316133226600_keae561-B17","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/annrheumdis-2016-210534","article-title":"Development and validation of a patient-reported outcome instrument for skin involvement in patients with systemic sclerosis","volume":"76","author":"Man","year":"2017","journal-title":"Ann. Rheum. Dis"},{"key":"2025050316133226600_keae561-B18","first-page":"1167","article-title":"Development and validation of a rheumatoid hand functional disability scale that assesses functional handicap","volume":"23","author":"Duru\u00f6z","year":"1996","journal-title":"J. Rheumatol"},{"key":"2025050316133226600_keae561-B19","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.semarthrit.2018.03.013","article-title":"Patient acceptable symptom state and minimal clinically important difference for patient-reported outcomes in systemic sclerosis: a secondary analysis of a randomized controlled trial comparing personalized physical therapy to usual care","volume":"48","author":"Daste","year":"2019","journal-title":"Semin. Arthritis Rheum"},{"key":"2025050316133226600_keae561-B20","author":"Portney","year":"2009"},{"key":"2025050316133226600_keae561-B21","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1213\/ANE.0000000000002864","article-title":"Correlation coefficients: appropriate use and interpretation","volume":"126","author":"Schober","year":"2018","journal-title":"Anesth. Analg"},{"key":"2025050316133226600_keae561-B22","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/03009742.2018.1523455","article-title":"Changes in disability and their relationship with skin thickening, in diffuse and limited cutaneous systemic sclerosis: a retrospective cohort study","volume":"48","author":"Peytrignet","year":"2019","journal-title":"Scand J Rheumatol"},{"key":"2025050316133226600_keae561-B23","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/rheumatology\/kex410","article-title":"Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study","volume":"57","author":"Peytrignet","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2025050316133226600_keae561-B24","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"2025050316133226600_keae561-B25","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1093\/rheumatology\/keaa911","article-title":"Disease progression in systemic sclerosis","volume":"60","author":"van Leeuwen","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025050316133226600_keae561-B26","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1002\/art.24681","article-title":"Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials","volume":"60","author":"Amjadi","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2025050316133226600_keae561-B27","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/1756-185X.12879","article-title":"Self-assessment of skin tightness severity by scleroderma patients","volume":"19","author":"Daungkum","year":"2016","journal-title":"Int. J. Rheum. Dis"},{"key":"2025050316133226600_keae561-B28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/rheumatology\/ken490","article-title":"Establishment and partial validation of a patient skin self-assessment questionnaire in systemic sclerosis","volume":"48","author":"Nagy","year":"2009","journal-title":"Rheumatology"},{"key":"2025050316133226600_keae561-B29","doi-asserted-by":"crossref","first-page":"152271","DOI":"10.1016\/j.semarthrit.2023.152271","article-title":"Teleconsultation in rheumatology: a literature review and opinion paper","volume":"63","author":"Avouac","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"2025050316133226600_keae561-B30","doi-asserted-by":"crossref","first-page":"e044483","DOI":"10.1136\/bmjopen-2020-044483","article-title":"A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol","volume":"11","author":"Spierings","year":"2021","journal-title":"BMJ Open"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae561\/60298191\/keae561.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/5\/2802\/60298191\/keae561.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/5\/2802\/60298191\/keae561.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T20:13:50Z","timestamp":1746303230000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/5\/2802\/7821206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,10,14]]},"published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae561","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,10,14]]}}}